Latest press releases Sep 26 2022 MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis Jul 26 2022 MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH May 12 2022 MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa View All News View All Press Releases + Upcoming events Nov 14 - Nov 15 2022 Guggenheim 4th Annual Immunology and Neurology Day Nov 15 - Nov 17 2022 Jefferies 2022 London Healthcare Conference Dec 8 2022 Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference View All Events View All Events + Corporate presentations Corporate presentation - July 2022 View All Presentations View All Presentations + IR contact details Dr. Atif Khan, Director of Strategic Planning and Projects e: ir@moonlaketx.com
Sep 26 2022 MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Jul 26 2022 MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
May 12 2022 MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake
MoonLake
